Nurix Therapeutics, Inc. NRIX Less than 12 months
Less than 12 months at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s less than 12 months.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s less than 12 months?
- Nurix Therapeutics, Inc. (NRIX) reported less than 12 months of $151.57M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s less than 12 months changed year-over-year?
- Nurix Therapeutics, Inc.'s less than 12 months increased by 68.5% year-over-year, from $89.95M to $151.57M.